Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BCDA

BCDA - BioCardia Inc Stock Price, Fair Value and News

$1.29-0.03 (-2.27%)
Market Closed

9/100

BCDA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

9/100

BCDA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.07

Target 3M

$1.21

Target 6M

$1.14

BCDA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCDA Price Action

Last 7 days

0.8%

Last 30 days

4.9%

Last 90 days

2.4%

Trailing 12 Months

-43.4%

BCDA RSI Chart

BCDA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BCDA Valuation

Market Cap

13.7M

Price/Earnings (Trailing)

-1.6

Price/Sales (Trailing)

237.87

EV/EBITDA

1.57

Price/Free Cashflow

-1.84

BCDA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.07

Target 3M

$1.21

Target 6M

$1.14

BCDA Fundamentals

BCDA Revenue

Revenue (TTM)

58.0K

BCDA Earnings

Earnings (TTM)

-8.5M

Earnings Growth (Yr)

14.62%

Earnings Growth (Qtr)

27.62%

BCDA Profitability

Operating Margin

100.00%

EBT Margin

9255.17%

Return on Equity

-325.09%

Return on Assets

-138.91%

Free Cashflow Yield

-54.49%

BCDA Investor Care

Shares Dilution (1Y)

131.50%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024468.0K428.0K71.0K58.0K
20231.4M425.0K570.0K477.0K
20221.1M1.2M1.3M1.4M
2021153.0K195.0K982.0K1.0M
2020532.5K473.5K313.5K145.0K
2019642.0K489.0K599.0K710.5K
2018541.0K668.0K622.0K625.0K
2017535.0K503.0K516.0K479.0K
2016946.0K965.0K961.0K576.0K
2015465.0K485.0K510.0K904.0K
2014328.0K364.0K389.0K427.0K
201389.0K141.0K193.0K268.0K
201224.5K37.0K49.5K62.0K
201100012.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About BioCardia Inc

BCDA
BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
 CEO
 WEBSITEbiocardia.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES30

BioCardia Inc Frequently Asked Questions

BCDA is the stock ticker symbol of BioCardia Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of BioCardia Inc is 13.69 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BCDA's fair value in chart for subscribers.

The fair value guage provides a quick view whether BCDA is over valued or under valued. Whether BioCardia Inc is cheap or expensive depends on the assumptions which impact BioCardia Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCDA.

As of Wed Jan 28 2026, BCDA's PE ratio (Price to Earnings) is -1.6 and Price to Sales (PS) ratio is 237.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCDA PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, BioCardia Inc has provided -0.173 (multiply by 100 for percentage) rate of return.